Historically, Alzheimer’s disease has been characterised by two key pathological hallmarks: amyloid plaques and tau tangles. Both have long been regarded as important diagnostic markers. However, ongoing scientific research is reshaping our understanding of the distinct roles these proteins play in the development and progression of the disease. Today, there is growing emphasis on amyloid as a marker for diagnosis, while tau is increasingly viewed as a key indicator of disease progression and severity rather than diagnosis alone. This evolving distinction is changing not only how Alzheimer’s disease is understood, but also how healthcare professionals approach early detection, treatment and patient management. The Growing Role of Anti-Amyloid Therapies in Alzheimer’s Disease Anti-amyloid therapies represent the first disease-modifying treatments developed specifically for Alzheimer’s disease. These therapies aim to reduce or remove amyloid plaques in the brain, targeting one of the defining biological features of the condition. Designed for people with early-stage Alzheimer’s disease, anti-amyloid treatments have demonstrated an ability to slow cognitive decline, marking a significant advancement in the treatment landscape. For many patients and healthcare providers, these therapies offer new hope for managing disease progression at an earlier stage. However, despite their promise, important questions remain surrounding patient eligibility, safety considerations and the broader role of tau pathology in the disease process. Patient Eligibility Challenges for Anti-Amyloid Treatment One of the emerging challenges associated with anti-amyloid therapies is ensuring that eligible patients are accurately identified and referred for treatment. A recent clinical trial conducted by the Mayo Clinic highlighted concerns that current eligibility criteria may unintentionally exclude patients with atypical Alzheimer’s disease. Unlike typical Alzheimer’s disease, where memory loss is often the earliest symptom, atypical Alzheimer’s disease can initially present with language difficulties or impairments in executive functioning. These differences can make diagnosis and assessment more complex. The study found that among 184 patients with biomarker-confirmed atypical Alzheimer’s disease, approximately 70% to 85% would have been excluded from anti-amyloid clinical trial participation due to poor performance on the Mini-Mental State Examination (MMSE). These findings raise important questions about whether existing assessment criteria adequately capture the full spectrum of Alzheimer’s disease presentations and whether some patients may face barriers to accessing emerging treatments. Understanding the Role of Tau in Alzheimer’s Disease Alongside discussions about patient eligibility, debate continues regarding the relative importance of amyloid and tau in driving symptomatic Alzheimer’s disease. Many researchers and neurologists highlight that tau pathology appears to correlate more closely with cognitive impairment, including memory loss, functional decline and disease severity. As a result, some experts question whether targeting amyloid alone will be sufficient to meaningfully alter the long-term trajectory of the disease. There is also growing interest in the potential of tau as an early biomarker. Evidence suggests that tau-related changes may be detectable years before significant amyloid accumulation, raising the possibility that identifying tau pathology earlier could support more effective intervention and disease modification strategies. As research progresses, understanding how amyloid and tau interact throughout the Alzheimer’s disease journey will remain a critical area of investigation. What Does This Mean for Pharmaceutical Companies? As the scientific understanding of Alzheimer’s disease continues to evolve, pharmaceutical companies face several important strategic considerations. Early Patient Identification Remains a Significant Challenge Early identification of patients with Alzheimer’s disease will continue to be a key challenge across healthcare systems. As biomarker testing becomes increasingly integrated into routine care, including the emergence of blood-based biomarkers that may facilitate earlier detection, primary care physicians will play an increasingly important role in the patient pathway. Equipping healthcare professionals with the knowledge, tools and confidence to recognise potential symptoms, interpret biomarker results and refer appropriate patients for further assessment will be critical to improving access to diagnosis and treatment. Brand Strategies Must Evolve Beyond Amyloid The scientific conversation around Alzheimer’s disease has already begun to move beyond amyloid alone. As understanding of tau pathology and its relationship with disease progression continues to develop, pharmaceutical companies will need to assess how emerging evidence influences healthcare professional beliefs, treatment decisions and perceptions of unmet need across the patient journey. Monitoring shifts in clinical opinion and evaluating the impact of new research will be essential for developing effective brand strategies, particularly as future therapies and diagnostic approaches potentially expand beyond amyloid-focused interventions. Looking Ahead The emergence of anti-amyloid therapies has marked a major milestone in Alzheimer’s disease treatment. However, evolving evidence around patient eligibility, biomarker testing and the role of tau highlights the complexity of the disease and the need for a broader understanding of its underlying biology. For pharmaceutical companies, healthcare professionals and researchers alike, staying ahead of these scientific developments will be crucial. As the field continues to advance, success will depend not only on improving treatment options but also on ensuring the right patients are identified early and supported throughout their care journey. Want to learn more about Alzheimer’s Disease and what the changing landscape means for your brand? Fill in the contact form below, or reach out to our Neuroscience experts at HRW_Synapse@hrwhealthcare.com By Zaniv Chhina and McKayla Grierson Apply Now!